Haemonetics Corporation — Form 10-Q Summary
Business and period: Haemonetics provides medical products and solutions for plasma and blood collection, hospital transfusion services, and surgical settings. This filing reports the fiscal third quarter and first nine months ended December 31, 2022; comparatives are the three and nine months ended January 1, 2022. Amounts below are in U.S. dollars.
Financial performance
| Metric | Quarter | Nine months |
|---|---|---|
| Revenue | $305.3 million, up 17.5% reported and 20.8% constant currency | $864.2 million, up 18.7% reported and 21.5% constant currency |
| Gross profit / margin | $158.7 million / 52.0%, versus 53.3% | $458.8 million / 53.1%, versus 50.7% |
| Operating income / margin | $43.3 million / 14.2%, versus $35.7 million / 13.7% | $120.8 million / 14.0%, versus $61.6 million / 8.5% |
| Net income | $32.9 million, versus $23.2 million | $86.0 million, versus $33.6 million |
| Diluted EPS | $0.64, versus $0.45 | $1.67, versus $0.65 |
| Operating cash flow | Not presented for the quarter | $193.4 million, versus $104.2 million |
Quarterly gross margin declined 1.3 percentage points year over year, while the nine-month margin increased 2.4 points. Management attributed gross profit growth to volume, pricing, and Operational Excellence Program savings, partly offset by inflation, supply-chain costs, and higher depreciation. Operating income growth also reflected increased Plasma and Hospital revenue, lower acquisition spending, and savings, partly offset by freight, sales and marketing, and performance-based compensation costs.
Segments and revenue trends
- Plasma: Third-quarter revenue grew 40.4% reported and 41.2% constant currency, driven by volume and price. The CSL Plasma supply agreement was extended through December 2025.
- Hospital: Third-quarter revenue grew 11.3% reported and 14.4% constant currency, led by Vascular Closure and growth in Hemostasis Management disposables and Transfusion Management. Vascular Closure revenue rose 32.6%.
- Blood Center: Third-quarter revenue declined 3.1% reported but grew 3.1% constant currency; nine-month revenue declined 5.6% reported and 1.1% constant currency. The nine-month decline primarily reflected lower apheresis disposable volume.
- International revenue fell 12.2% reported for the quarter, including a 9.0% adverse currency impact. U.S. revenue grew 34.0%.
Cash, debt, and liquidity
- Cash and equivalents were $224.0 million at December 31, 2022, down from $259.5 million at April 2, 2022. Working capital was $479.4 million; the current ratio was 3.1.
- Net debt was $542.8 million, compared with $514.1 million at fiscal year-end. This reflects total debt exceeding cash.
- Debt included $276.5 million outstanding on the term loan, at a 6.0% effective rate, and $491.5 million net carrying value on $500 million of 0% convertible notes due 2026. No revolving-credit borrowings were outstanding; the facility provides $420 million of capacity and matures in June 2025.
- The company refinanced its credit facilities in July 2022 and reported compliance with financial and other bank covenants at quarter-end. Interest-rate swaps hedge a substantial portion of term-loan exposure.
- Nine-month investing cash outflow was $125.8 million, including $98.3 million of capital expenditures and $33.2 million of other investments. Financing cash outflow was $98.8 million, including a $75 million share repurchase and contingent-consideration payments.
Management said cash, operating cash flow, and the revolving facility should be sufficient to fund requirements for at least the next 12 months. The company invested €30 million in Vivasure Medical during fiscal 2023.
Outlook, risks, and notable items
- No specific revenue or earnings guidance for the remainder of fiscal 2023 is stated in the provided filing text. Management expected global supply-chain inflationary pressures to continue through fiscal 2023 and cautioned that pricing and productivity may not fully offset cost increases.
- The revised Operational Excellence Program is expected to incur total charges of $95–$105 million by the end of fiscal 2025 and generate annualized gross savings of $115–$125 million when complete. Cumulative charges were $66.4 million at December 31, 2022.
- The board authorized up to $300 million in repurchases over three years. A $75 million accelerated repurchase was completed; $225 million remained authorized at quarter-end.
- Haemonetics faces foreign-exchange and interest-rate exposure, customer concentration in Plasma, product quality and regulatory risks, supply and raw-material risks, and risks related to restructuring and execution. It reported no material changes to the risk factors in its prior Form 10-K.
- A putative Illinois biometric-privacy class action remains pending; the company said it would defend the case and could not reasonably estimate potential loss. In a separate qui tam matter involving devices and reporting, the DOJ and 31 states declined to intervene after investigation; the case was unsealed and remains a legal matter.
- Management reported effective disclosure controls as of December 31, 2022, with no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether rapid Plasma and Hospital growth continues and whether Blood Center weakness stabilizes.
- Whether gross-margin pressure from inflation, freight, and depreciation is offset by pricing and productivity savings.
- Execution and cash costs of the Operational Excellence Program, including realization of the stated savings target.
- Debt service, covenant headroom, and sensitivity to interest rates despite the swaps; confirm liquidity against planned capital spending and repurchases.
- Developments and potential financial exposure in the biometric-privacy and qui tam litigation matters.
- Currency effects: reported growth materially differed from constant-currency growth, particularly in international markets.